Insulin degludec

Indications for Use

Insulin degludec is prescribed to help manage blood glucose (sugar) levels in people with diabetes. It is used for two primary conditions:

• Type 1 diabetes: A condition where the body does not produce enough insulin.
• Type 2 diabetes: A condition where the body does not use insulin properly or cannot make enough to maintain healthy blood sugar levels.

This medication is a basal (long-acting) insulin. It is designed to provide a steady level of insulin in the bloodstream over a long period. Because it works slowly and consistently, it helps keep blood sugar levels stable between meals and overnight.

Usage in Different Populations

Insulin degludec is approved for use in both adults and pediatric patients. For children, it is generally used for those who are at least 1 year old.

Comprehensive Treatment Plan

This medication is intended to be part of a complete treatment program that often includes a specific diet, regular physical exercise, and blood sugar monitoring. In many cases, it is used in combination with other diabetes medications or short-acting insulins to manage blood sugar spikes that occur after eating.

Mechanism of Action

Insulin degludec is an ultra-long-acting basal insulin. It works by replacing the insulin that the body normally produces, helping to regulate blood sugar levels in people with diabetes.

This medication performs several key functions in the body:

• Glucose Transport: It helps move sugar from the bloodstream into other body tissues, such as muscle and fat cells, where it can be used for energy.
• Liver Regulation: It signals the liver to stop producing and releasing more sugar into the blood.
• Metabolic Support: It assists the body in properly processing fats and proteins.

Duration of Effect

Unlike short-acting insulins, insulin degludec is designed to release slowly into the bloodstream. After it is injected under the skin, it forms a depot that provides a steady, continuous level of insulin for a long period. This helps maintain stable blood sugar levels between meals and overnight, with effects that can last for 42 hours or more.

Common Side Effects

The most common side effect of insulin degludec is hypoglycemia (low blood sugar). Other common side effects include:

• Injection site reactions such as pain, redness, or swelling.
• Changes in skin thickness or pits at the injection site (lipodystrophy).
• Weight gain.
• Swelling of the hands and feet (edema).
• Headache or symptoms of the common cold.
• Itching or rash.

Serious Side Effects

Some side effects can be severe and require immediate medical care. These include:

• Severe hypoglycemia: This can lead to confusion, seizures, or loss of consciousness if not treated promptly.
• Severe allergic reactions: Symptoms may include a whole-body rash, trouble breathing, fast pulse, or swelling of the face, lips, and throat.
• Low potassium (hypokalemia): This may cause muscle cramps, weakness, or abnormal heart rhythms.
• Heart failure: This may occur if insulin is used with certain other diabetes medications called thiazolidinediones (TZDs). Symptoms include shortness of breath, sudden weight gain, and swelling of the ankles or feet.

Hypoglycemia

Low blood sugar (hypoglycemia) is the most common adverse reaction and can be life-threatening. The risk of hypoglycemia increases with changes in insulin dose, meal patterns, or physical activity. Severe hypoglycemia can lead to seizures, loss of consciousness, or death.

Hypersensitivity and Allergic Reactions

Severe, life-threatening allergic reactions, including anaphylaxis, can occur with insulin products. If a serious reaction develops, the medication must be stopped and medical treatment sought immediately.

Hypokalemia

All insulin products, including insulin degludec, cause a shift in potassium from the blood into the cells. This can lead to low potassium levels (hypokalemia), which, if untreated, may cause respiratory paralysis, heart rhythm abnormalities, or death. Monitoring is particularly important for patients at risk of low potassium.

Fluid Retention and Heart Failure

Using insulin degludec in combination with thiazolidinediones (TZDs) can cause fluid retention and heart failure. Patients should be monitored for signs such as shortness of breath, swelling of the ankles or feet, and sudden weight gain.

Medication Errors

Accidental mix-ups between insulin degludec and other insulin products have been reported. To avoid errors, the label should be checked before every injection. Additionally, insulin pens must never be shared between patients, even if the needle is changed, because of the risk of spreading bloodborne pathogens.

Contraindications

• Do not use during episodes of hypoglycemia.
• Do not use if there is a known hypersensitivity to insulin degludec or any of its ingredients.

Pregnancy

Maintaining stable blood glucose levels is essential during pregnancy to reduce the risk of complications for both the parent and the developing baby. Clinical studies have not shown an increased risk of major birth defects or other adverse outcomes when insulin degludec is used during pregnancy compared to other long-acting insulins.

Insulin requirements typically fluctuate throughout the course of pregnancy and the period immediately following delivery:

• First trimester: Insulin needs may decrease.
• Second and third trimesters: Insulin needs usually increase.
• Postpartum: Insulin requirements often drop rapidly after the baby is born.

Breastfeeding

Insulin degludec is generally considered safe to use while breastfeeding. Because insulin is a naturally occurring hormone in the body, it is not expected to cause harm to a nursing infant. However, breastfeeding can affect blood sugar levels, and insulin doses may need to be adjusted during the postpartum period.

It is important to discuss any plans for pregnancy or breastfeeding with a healthcare provider to ensure blood sugar levels are monitored closely and medication doses are managed appropriately.

Available Forms

Insulin degludec is a solution for subcutaneous injection. It is available in the following formats:

• Prefilled disposable pens
• Multi-dose vials

Insulin degludec is also available in combination with other medications, including:

• Insulin degludec and insulin aspart, provided in prefilled pens.
• Insulin degludec and liraglutide, provided in prefilled pens.

FDA Approval and Indications

Insulin degludec was approved by the U.S. Food and Drug Administration (FDA) in 2015. It is indicated to improve glycemic control in adults and pediatric patients aged 1 year and older with diabetes mellitus. It is available as a standalone long-acting insulin and in combination with other medications, such as insulin aspart or liraglutide.

Safety Monitoring and Communications

The FDA monitors the safety of insulin degludec through the FDA Adverse Event Reporting System (FAERS). The following safety signals have been identified:

• Medication Errors: In 2018 and 2020, the FDA identified potential signals regarding medication errors, including instances of the wrong drug or wrong dose being administered. The FDA evaluated these reports to determine if regulatory action or changes to the labeling were necessary.

Regulatory Requirements

Insulin degludec does not currently have a Boxed Warning or a Risk Evaluation and Mitigation Strategy (REMS) program. It is classified as a prescription-only medication.

Factors Influencing Cost

The price of insulin degludec can vary significantly based on the following factors:

• Generic vs. Brand Name: Insulin degludec is available as a brand-name medication and as a generic. Generic versions are often more affordable than brand-name products.
• Insurance Coverage: Out-of-pocket costs are largely determined by a patient's health insurance plan, including its formulary status, deductibles, and copayments. Some insurance plans may only cover specific brands or versions of the drug.
• Pharmacy Selection: Prices may differ between retail pharmacies, mail-order pharmacies, and local providers.
• Dosage and Packaging: The cost is affected by the concentration of the insulin (such as U-100 or U-200) and whether it is dispensed in vials or pre-filled pens.

Patients who are uninsured or underinsured may be able to access patient assistance programs or manufacturer savings cards to help reduce costs. It is advisable to consult with a pharmacist or insurance provider to determine the exact cost for a specific prescription.